Current markers of the Athlete Blood Passport do not flag microdose EPO doping

European Journal of Applied Physiology

Volumn 111, Issue 9, 2011, Pages 2307-2314

  Ashenden, Michael ^a   Gough, Clare E ^b,c   Garnham, Andrew ^d   Gore, Christopher J ^b,e   Sharpe, Ken ^f  

^a SIAB Research consortium   (Australia)

^b AUSTRALIAN INSTITUTE OF SPORT   (Australia)

^c UNIVERSITY OF CANBERRA   (Australia)

^d DEAKIN UNIVERSITY   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Blood doping; Erythropoietin; Reticulocytes; Sysmex

Indexed keywords

BIOLOGICAL MARKER; ERYTHROPOIETIN; PERFORMANCE ENHANCING SUBSTANCE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; ATHLETE; BLOOD; CLINICAL TRIAL; DOPING; DOSE RESPONSE; HUMAN; LIMIT OF DETECTION; MALE; METHODOLOGY; REFERENCE VALUE; RESISTANCE TRAINING; SENSITIVITY AND SPECIFICITY; STANDARD; SUBSTANCE ABUSE;

ADULT; ATHLETES; BIOLOGICAL MARKERS; DOPING IN SPORTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; HUMANS; LIMIT OF DETECTION; MALE; PERFORMANCE-ENHANCING SUBSTANCES; RECOMBINANT PROTEINS; REFERENCE VALUES; RESISTANCE TRAINING; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE DETECTION; YOUNG ADULT;

EID: 80053895084     PISSN: 14396319     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00421-011-1867-6     Document Type: Article

References (25)

1. Ashenden M, Varlet-Marie E, Lasne F, Audran M (2006) The effects of microdose recombinant human erythropoietin regimens in athletes. Haematologica 91: 1143-1144
2. Ashenden MJ, Sharpe K, Damsgaard R, Jarvis L (2004) Standardization of reticulocyte values in an antidoping context. Am J Clin Pathol 121: 816-825
3. Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart M-T, Marion B, Bressolle F (1999) Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc 31: 639-645
4. Banfi G, Tavana R, Freschi M, Lundby C (2010) Reticulocyte profile in top-level alpine skiers during four consecutive competitive seasons. Eur J Appl Physiol 109: 561-568
5. Berglund B, Ekblom B (1991) Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med 229: 125-130
6. Borno A, Aachmann-Andersen NJ, Munch-Andersen T, Hulston CJ, Lundby C (2010) Screening for recombinant human erythropoietin using [Hb], reticulocytes, the OFF(hr score), OFF(z score) and Hb(z score): status of the Blood Passport. Eur J Appl Physiol 109: 537-543
7. Damsgaard R, Munch T, Moerkeberg J, Mortensen SP, Gonzalez-Alonso J (2006) Effects of blood withdrawal and reinfusion on biomarkers of erythropoiesis in humans: implications for antidoping strategies. Haematologica 91: 1006-1008
8. Gore CJ, Parisotto R, Ashenden MJ, Stray-Gundersen J, Sharpe K, Hopkins W, Emslie KR, Howe C, Trout GJ, Kazlauskas R, Hahn AG (2003) Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica 88: 333-344
9. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50: 702-712
10. Lasne F (2001) Double-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures. J Immunol Methods 253: 125-131
11. Lundby C, Achman-Andersen NJ, Thomsen JJ, Norgaard AM, Robach P (2008) Testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing. J Appl Physiol 105: 417-419
12. Morkeberg J, Belhage B, Ashenden M, Borno A, Sharpe K, Dziegiel MH, Damsgaard R (2009a) Screening for autologous blood transfusions. Int J Sports Med 30: 285-292
13. Morkeberg J, Saltin B, Belhage B, Damsgaard R (2009b) Blood profiles in elite cross-country skiers: a 6-year follow-up. Scand J Med Sci Sports 19: 198-205
14. Morkeberg J, Sharpe K, Belhage B, Damsgaard R, Schmidt W, Prommer N, Gore CJ, Ashenden MJ (2009c) Detecting autologous blood transfusions: a comparison of three passport approaches and four blood markers. Scand J Med Sci Sports. doi: 10.1111/j.1600-0838.2009.01033.x
15. Morkeberg JS, Belhage B, Damsgaard R (2009d) Changes in blood values in elite cyclist. Int J Sports Med 30: 130-138
16. Parisotto R, Wu M, Ashenden MJ, Emslie KR, Gore CJ, Howe C, Kazlauskas R, Sharpe K, Trout GJ, Xie M (2001) Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 86: 128-137
17. Russell G, Gore CJ, Ashenden MJ, Parisotto R, Hahn AG (2002) Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. Eur J Appl Physiol 86: 442-449
18. Schmidt W, Prommer N (2005) The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely. Eur J Appl Physiol 95: 486-495
19. Schumacher YO, Wenning M, Robinson N, Sottas PE, Ruecker G, Pottgiesser T (2010) Diurnal and exercise-related variability of haemoglobin and reticulocytes in athletes. Int J Sports Med 31: 225-230
20. Sharpe K, Ashenden MJ, Schumacher YO (2006) A third generation approach to detect erythropoietin abuse in athletes. Haematologica 91: 356-363
21. Sottas P-E, Robinson N, Saugy M (2008) A forensic approach to the interpretation of blood doping markers. Law, Probability Risk 7: 191-210
22. Thomsen JJ, Rentsch RL, Robach P, Calbet JA, Boushel R, Rasmussen P, Juel C, Lundby C (2007) Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity. Eur J Appl Physiol 101: 481-486
23. WADA (2009) Athlete biological passport operating guidelines
24. Zorzoli M (2005) Blood monitoring in anti-doping setting. In: Schanzer WHG, Gotzmann A (eds) Recent advances in doping analysis. Sport und Buch Strauss, Koln, pp 255-264
25. Zorzoli M, Rossi F (2010) Implementation of the biological passport: the experience of the International Cycling Union. Drug Test Anal. doi: 10.1002/dta.173